GlassScriptPhysician profile
Doru M Paul
NPI 1629055959
$13,582.72
in general payments reported to CMS, 2019-2025
25 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $21.19 · 2021: $123 · 2022: $149 · 2023: $175 · 2024: $215 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757 · Education: $53.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.96 |
| Education | $53.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $12,012.27 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $247.13 | 2019-2025 | Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $182.87 | 2022-2025 | Datroway, Enhertu |
| Amgen INC. | $161.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $140.18 | 2019-2023 | Opdivo |
| Genzyme Corporation | $122.88 | 2021 | |
| Tersera Therapeutics LLC | $121.30 | 2023-2024 | Xermelo |
| Novartis Pharmaceuticals Corporation | $86.27 | 2024-2025 | |
| Astellas Pharma US INC | $62.90 | 2025 | Vyloy |
| Merck Sharp & Dohme LLC | $61.09 | 2024-2025 | Keytruda, Keytruda Qlex |
| Lilly USA, LLC | $53.86 | 2025 | |
| Incyte Corporation | $49.92 | 2025 | Pemazyre, Zynyz |
| Abbvie INC. | $47.61 | 2024-2025 | |
| Advanced Accelerator Applications | $35.90 | 2019 | |
| Beone Medicines USA, INC. | $31.34 | 2025 | Tevimbra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $30.80 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $28.43 | 2024 | Alunbrig |
| Mirati Therapeutics, INC. | $23.88 | 2023 | Krazati |
| Spectrum Pharmaceuticals INC. | $22.46 | 2023 | Rolvedon |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2020 | |
| Array Biopharma INC | $20.96 | 2025 | Braftovi, Lorbrena |
| Foundation Medicine, INC. | $17.50 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doru Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.